Type 2 Diabetes

A 3 million-plus patient longitudinal study found the drug class was no worse for amputation risks than other diabetes therapies, despite recent conflicting studies.

Now that SGLT-2 inhibitors have reached the market, how will clinicians compare their benefits in patients?

How the effective cardiovascular drug class have reach a state of impending head-to-head trials.

A prospective study found that daily dapagliflozin significantly improved mitral flow, left ventricular mass index, and left atrial volume index after 6 months of treatment.

No head-to-head trials exist for the inhibitors, but current data shows consistency across the board for each drug.

Recently new therapy options are becoming more evidenced by the day. But have they reached their fullest potential?

Immediate, intensive treatment for newly diagnosed diabetes patients may be necessary to avoid irreversible long-term risk for diabetic complications and mortality, a new study shows.

The 100 Units/mL/ 300 mcg/mL-dosed therapy was previously approved as an add-on therapy to diet and exercise in adults with T2D.

A large population trial conducted in Bangladesh shows that community mobilization based on education and action may be an effective tool for preventing and controlling Type 2 diabetes.

The t:Slim X2 insulin pump is both compatible with outside therapy systems, and capable of delivering insulin on its own.

The CAROLINA cardiovascular safety study found that linagliptin was non-inferior to glimepiride in time to a composite cardiovascular endpoint.

Current smokers with type 1 diabetes had higher A1c values and greater risk of microvascular complications compared with former and never smokers, according to results of a new study.

Authors of a new study found that patients who develop diabetes later in life have a higher risk of cardiovascular disease.